Bayhill Therapeutics enters exclusive, worldwide collaboration with Genentech for BHT-3021 in Type 1 diabetes

Bayhill Therapeutics enters exclusive, worldwide collaboration with Genentech for BHT-3021 in Type 1 diabetes

 
SAN MATEO, Calif.–(BUSINESS WIRE)–Bayhill Therapeutics Inc. announced today that it has entered into an exclusive worldwide license agreement for the development and potential commercialization of BHT-3021 with Genentech, Inc. a wholly-owned member of the Roche Group. BHT-3021 is Bayhill’s DNA based antigen specific immunotherapy currently in a phase I/II clinical trial in patients with type 1 diabetes (T1D).

Bayhill Therapeutics presents data from a Phase 2 trial of BHT-3009 in multiple sclerosis at American Academy of Neurology 60th annual meeting

 
PALO ALTO, Calif., April 16, 2008 – (BUSINESS WIRE) – Bayhill Therapeutics, Inc. today announced that the Company’s co-founder and Vice President of Research, Hideki Garren, M.D., Ph.D., gave a podium presentation at the American Academy of Neurology 60th Annual Meeting (AAN) in Chicago. Dr. Garren’s presentation, “Results from a Phase II Trial of a Myelin Basic Protein Encoding DNA Vaccine for Relapsing Multiple Sclerosis,” provides further analysis of data from a Phase II study evaluating BHT-3009, a tolerizing DNA vaccine for multiple sclerosis (MS).